297 related articles for article (PubMed ID: 30318009)
1. Isolation, Purification, Characterisation and Application of L-ASNase: A Review.
Paul T; Mondal A; Bandyopadhyay TK
Recent Pat Biotechnol; 2019; 13(1):33-44. PubMed ID: 30318009
[TBL] [Abstract][Full Text] [Related]
2. Biochemical characterization and immobilization of Erwinia carotovoral-asparaginase in a microplate for high-throughput biosensing of l-asparagine.
Labrou NE; Muharram MM
Enzyme Microb Technol; 2016 Oct; 92():86-93. PubMed ID: 27542748
[TBL] [Abstract][Full Text] [Related]
3. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum.
Lanvers C; Vieira Pinheiro JP; Hempel G; Wuerthwein G; Boos J
Anal Biochem; 2002 Oct; 309(1):117-26. PubMed ID: 12381370
[TBL] [Abstract][Full Text] [Related]
4. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
Dibenedetto SP; Di Cataldo A; Ragusa R; Meli C; Lo Nigro L
J Clin Oncol; 1995 Feb; 13(2):339-44. PubMed ID: 7844595
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic l-asparaginase: upstream, downstream and beyond.
Lopes AM; Oliveira-Nascimento L; Ribeiro A; Tairum CA; Breyer CA; Oliveira MA; Monteiro G; Souza-Motta CM; Magalhães PO; Avendaño JG; Cavaco-Paulo AM; Mazzola PG; Rangel-Yagui CO; Sette LD; Converti A; Pessoa A
Crit Rev Biotechnol; 2017 Feb; 37(1):82-99. PubMed ID: 26694875
[TBL] [Abstract][Full Text] [Related]
6. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.
Albertsen BK; Schrøder H; Ingerslev J; Jakobsen P; Avramis VI; Müller HJ; Carlsen NT; Schmiegelow K
Br J Haematol; 2001 Dec; 115(4):983-90. PubMed ID: 11843837
[TBL] [Abstract][Full Text] [Related]
7. Towards development of biobetter: L-asparaginase a case study.
Tripathy RK; Anakha J; Pande AH
Biochim Biophys Acta Gen Subj; 2024 Jan; 1868(1):130499. PubMed ID: 37914146
[TBL] [Abstract][Full Text] [Related]
8. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells.
Aslanian AM; Kilberg MS
Biochem J; 2001 Aug; 358(Pt 1):59-67. PubMed ID: 11485552
[TBL] [Abstract][Full Text] [Related]
9. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
[TBL] [Abstract][Full Text] [Related]
10. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).
Panosyan EH; Grigoryan RS; Avramis IA; Seibel NL; Gaynon PS; Siegel SE; Fingert HJ; Avramis VI
Anticancer Res; 2004; 24(2C):1121-5. PubMed ID: 15154634
[TBL] [Abstract][Full Text] [Related]
11. Expanding targets for a metabolic therapy of cancer: L-asparaginase.
Covini D; Tardito S; Bussolati O; Chiarelli LR; Pasquetto MV; Digilio R; Valentini G; Scotti C
Recent Pat Anticancer Drug Discov; 2012 Jan; 7(1):4-13. PubMed ID: 21854356
[TBL] [Abstract][Full Text] [Related]
12. Immobilization of L-asparaginase into a biocompatible poly(ethylene glycol)-albumin hydrogel: evaluation of performance in vivo.
Jean-François J; D'Urso EM; Fortier G
Biotechnol Appl Biochem; 1997 Dec; 26(3):203-12. PubMed ID: 9428158
[TBL] [Abstract][Full Text] [Related]
13. Enzyme Engineering Strategies for the Bioenhancement of L-Asparaginase Used as a Biopharmaceutical.
Miranda J; Lefin N; Beltran JF; Belén LH; Tsipa A; Farias JG; Zamorano M
BioDrugs; 2023 Nov; 37(6):793-811. PubMed ID: 37698749
[TBL] [Abstract][Full Text] [Related]
14. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
15. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
[TBL] [Abstract][Full Text] [Related]
16. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
Avramis VI; Tiwari PN
Int J Nanomedicine; 2006; 1(3):241-54. PubMed ID: 17717965
[TBL] [Abstract][Full Text] [Related]
17. Microbial production, molecular modification, and practical application of l-Asparaginase: A review.
Wang Y; Xu W; Wu H; Zhang W; Guang C; Mu W
Int J Biol Macromol; 2021 Sep; 186():975-983. PubMed ID: 34293360
[TBL] [Abstract][Full Text] [Related]
18. Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
Chan WK; Horvath TD; Tan L; Link T; Harutyunyan KG; Pontikos MA; Anishkin A; Du D; Martin LA; Yin E; Rempe SB; Sukharev S; Konopleva M; Weinstein JN; Lorenzi PL
Mol Cancer Ther; 2019 Sep; 18(9):1587-1592. PubMed ID: 31209181
[TBL] [Abstract][Full Text] [Related]
19. Recent Strategies and Applications for l-Asparaginase Confinement.
Nunes JCF; Cristóvão RO; Freire MG; Santos-Ebinuma VC; Faria JL; Silva CG; Tavares APM
Molecules; 2020 Dec; 25(24):. PubMed ID: 33321857
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, characterization and immunogenicity of silk fibroin-L-asparaginase bioconjugates.
Zhang YQ; Zhou WL; Shen WD; Chen YH; Zha XM; Shirai K; Kiguchi K
J Biotechnol; 2005 Nov; 120(3):315-26. PubMed ID: 16102867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
